New York State Common Retirement Fund Has $438,000 Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (2024)

New York State Common Retirement Fund trimmed its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 10.2% in the fourth quarter, HoldingsChannel reports. The firm owned 48,722 shares of the biotechnology company’s stock after selling 5,547 shares during the quarter. New York State Common Retirement Fund’s holdings in Aurinia Pharmaceuticals were worth $438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of AUPH. SG Americas Securities LLC bought a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth approximately $165,000. Raymond James & Associates boosted its stake in Aurinia Pharmaceuticals by 37.8% in the 3rd quarter. Raymond James & Associates now owns 16,951 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 4,651 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Aurinia Pharmaceuticals by 33.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,244 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 6,513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Aurinia Pharmaceuticals by 8.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 63,788 shares of the biotechnology company’s stock worth $496,000 after buying an additional 5,012 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 560.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 100,706 shares of the biotechnology company’s stock worth $782,000 after buying an additional 85,458 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $5.31 on Thursday. The firm has a 50 day moving average of $5.10 and a 200-day moving average of $6.97. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $12.43. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $757.52 million, a PE ratio of -12.35 and a beta of 1.36.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The firm had revenue of $45.10 million for the quarter, compared to analyst estimates of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative return on equity of 15.06%. The firm’s revenue for the quarter was up 58.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.18) earnings per share. On average, equities research analysts predict that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AUPH has been the topic of several research reports. Cantor Fitzgerald decreased their price target on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Royal Bank of Canada decreased their target price on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. Jefferies Financial Group reduced their price target on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating on the stock in a research report on Friday, February 16th. Finally, StockNews.com upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Aurinia Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $10.00.

Check Out Our Latest Research Report on AUPH

Aurinia Pharmaceuticals Company Profile

(Free Report)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Further Reading

• Five stocks we like better than Aurinia Pharmaceuticals
• Russell 2000 Index, How Investors Use it For Profitable Trading
• How to Buy the Dip and Sell the Rip on Your Stocks with Options
• Following Congress Stock Trades
• 3 Hot Buyback Plans Supporting Price Action in 2024
• What to Know About Investing in Penny Stocks
• Stocks With Subscription Based Revenue Offer Inflation Protection

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP).

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.